Martin Shkreli

Martin Shkreli (, born March 17, 1983) is an American businessman, former hedge fund manager and convicted fraudster. He is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, MSMB Healthcare, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin, and founder and former CEO of Turing Pharmaceuticals.

In September 2015, Shkreli received widespread criticism when Turing got the manufacturing license for the antiparasitic drug Daraprim and raised its price by a factor of 56 (from $13.50 to $750 per pill), leading him to be referred to as "the most hated man in America" and "pharma bro".

In December 2015, Shkreli was arrested by the FBI after being indicted on federal charges of securities fraud. He subsequently as CEO of Turing Pharmaceuticals and was replaced by the company's board chairman, Ron Tilles. Shkreli was convicted of two counts of securities fraud and one count of conspiring to commit securities fraud in August 2017.


